BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+17.56%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.54B
AUM Growth
+$6.54B
(+5.3%)
Cap. Flow
-$366M
Cap. Flow
% of AUM
-5.6%
Top 10 Holdings %
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18
Top Buys
| 1 |
Immunocore
IMCR
|
$65.3M |
| 2 |
Biohaven
BHVN
|
$46M |
| 3 |
Moderna
MRNA
|
$41.1M |
| 4 |
GE HealthCare
GEHC
|
$40.4M |
| 5 |
Boston Scientific
BSX
|
$30.3M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$108M |
| 2 |
UnitedHealth
UNH
|
$63.2M |
| 3 |
Evolent Health
EVH
|
$42.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$34.5M |
| 5 |
IQVIA
IQV
|
$34M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Industrials | 0.83% |
| 3 | Energy | 0.03% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $441M | 6.74% | 8,713,987 -519,713 | -6% | -$26.3M |
|
2
argenx
ARGX
$43.6B
| $331M | 5.06% | 869,208 -42,322 | -5% | -$16.1M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $320M | 4.9% | 2,430,500 -153,050 | -6% | -$20.2M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $300M | 4.58% | 736,390 -266,345 | -27% | -$108M |
|
5
Intuitive Surgical
ISRG
$170B
| $281M | 4.29% | 832,041 +3,042 | +0.4% | +$1.03M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $220M | 3.36% | 3,066,400 -103,850 | -3% | -$7.44M |
|
|
7
Moderna
MRNA
$9.37B
| $190M | 2.9% | 1,908,420 +413,095 | +28% | +$41.1M |
|
|
8
Boston Scientific
BSX
$156B
| $183M | 2.8% | 3,170,603 +524,308 | +20% | +$30.3M |
|
9
Alnylam Pharmaceuticals
ALNY
$58.5B
| $169M | 2.59% | 885,318 -9,027 | -1% | -$1.73M |
|
10
Abbott
ABT
$231B
| $169M | 2.59% | 1,535,656 -25,312 | -2% | -$2.79M |
|
11
Revolution Medicines
RVMD
$7.1B
| $146M | 2.23% | 5,091,000 +369,500 | +8% | +$10.6M |
|
12
Stryker
SYK
$150B
| $139M | 2.13% | 465,724 -9,889 | -2% | -$2.96M |
|
13
Incyte
INCY
$16.5B
| $135M | 2.07% | 2,156,719 -334,731 | -13% | -$21M |
|
|
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
| $114M | 1.75% | 1,833,165 -419,686 | -19% | -$26.1M |
|
15
DexCom
DXCM
$29.5B
| $113M | 1.74% | 914,593 +228,860 | +33% | +$28.4M |
|
16
Arvinas
ARVN
$568M
| $103M | 1.58% | 2,507,731 +382,531 | +18% | +$15.7M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $95.8M | 1.47% | 2,416,296 +516,296 | +27% | +$20.5M |
|
18
MacroGenics
MGNX
$112M
| $95.8M | 1.46% | 9,953,313 +150,000 | +2% | +$1.44M |
|
19
Becton Dickinson
BDX
$55.3B
| $94.6M | 1.45% | 388,068 +83,838 | +28% | +$20.4M |
|
20
Agios Pharmaceuticals
AGIO
$2.19B
| $89.3M | 1.37% | 4,011,000 -2,500 | -0.1% | -$55.7K |
|
21
Medtronic
MDT
$119B
| $80M | 1.22% | 970,772 +329,280 | +51% | +$27.1M |
|
|
22
Evolent Health
EVH
$1.12B
| $78.5M | 1.2% | 2,376,992 -1,300,123 | -35% | -$42.9M |
|
23
Edwards Lifesciences
EW
$47.8B
| $77.7M | 1.19% | 1,018,998 -6,459 | -0.6% | -$492K |
|
24
Exact Sciences
EXAS
$8.98B
| $77.5M | 1.19% | 1,047,786 -72,033 | -6% | -$5.33M |
|
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| $76.1M | 1.16% | 3,513,351 | – | – |
|